[Chronic obstructive pulmonary disease and heart failure].
Chronic obstructive pulmonary disease (COPD) is commonly associated with heart failure. Individuals with COPD have a 4.5-fold greater risk of developing heart failure than those without. The sensitivity and specificity of clinical judgment in the diagnosis of heart failure in patients with COPD can be enhanced by biological markers such as B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide. Correct interpretation of imaging results (mainly echocardiographic findings) and lung function tests can also help establish the co-occurrence of both conditions. There is little evidence on the management of patients with COPD and heart failure, although treatment of COPD undeniably affects the clinical course of patients with heart failure and viceversa.
Villar Alvarez
Felipe
F
Servicio de Neumología, Fundación Jiménez Díaz - CAPIO, Madrid, España.
Méndez Bailón
Manuel
M
de Miguel Díez
Javier
J
D000318:Adrenergic beta-Agonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D009320:Atrial Natriuretic Factor / Q000097:blood; D015415:Biomarkers; D001993:Bronchodilator Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D002097:C-Reactive Protein / Q000032:analysis; D003131:Combined Modality Therapy; D000075202:Contraindications; D004347:Drug Interactions; D006333:Heart Failure / Q000097:blood / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D006334:Heart Function Tests; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000209:etiology; D020097:Natriuretic Peptide, Brain / Q000097:blood; D010102:Oxygen Inhalation Therapy; D010446:Peptide Fragments / Q000097:blood; D029424:Pulmonary Disease, Chronic Obstructive / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy; D011660:Pulmonary Heart Disease / Q000188:drug therapy / Q000209:etiology; D012121:Respiration, Artificial; D012129:Respiratory Function Tests
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D015415:Biomarkers; D001993:Bronchodilator Agents; D010446:Peptide Fragments; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain; D009320:Atrial Natriuretic Factor; D002097:C-Reactive Protein